{"id":55,"date":"2026-10-06T01:15:46","date_gmt":"2026-10-06T01:15:46","guid":{"rendered":"https:\/\/defianttx.com\/?page_id=55"},"modified":"2026-10-25T19:30:04","modified_gmt":"2026-10-25T19:30:04","slug":"immune-organs-for-solid-tumors","status":"publish","type":"page","link":"https:\/\/defianttx.com\/","title":{"rendered":"Immune Organs for Solid Tumors"},"content":{"rendered":"\n<style>\nbody:has(.defiant-rebrand){background:#f8f6f0;color:#272720}\nbody:has(.defiant-rebrand) .wp-site-blocks{padding:0}\nbody:has(.defiant-rebrand) .wp-site-blocks>header,body:has(.defiant-rebrand) .wp-site-blocks>footer,body:has(.defiant-rebrand) .wp-block-post-title{display:none}\nbody:has(.defiant-rebrand) .wp-site-blocks>main{margin:0!important;padding:0!important}\nbody:has(.defiant-rebrand) .entry-content{margin:0!important;padding:0!important}\n.defiant-rebrand{max-width:none!important;width:100%;margin:0!important;font-family:Inter,Arial,sans-serif;font-size:17px;line-height:1.65;color:#272720;background:#f8f6f0}\n.defiant-rebrand *{box-sizing:border-box}\n.defiant-rebrand .dx-wrap{width:min(1160px,calc(100% - 80px));max-width:none;margin:0 auto}\n.defiant-rebrand .dx-header{display:flex;align-items:center;justify-content:space-between;gap:28px;padding:28px 0;border-bottom:1px solid #d9d6cc}\n.defiant-rebrand .dx-logo{width:185px;margin:0;line-height:0}\n.defiant-rebrand .dx-logo img{width:100%;height:auto}\n.defiant-rebrand .dx-nav{display:flex;flex-wrap:wrap;gap:26px;margin:0;font-size:13px;font-weight:600}\n.defiant-rebrand a{color:#9d2333;text-underline-offset:5px}\n.defiant-rebrand a:hover{color:#651522}\n.defiant-rebrand a:focus-visible{outline:3px solid #9d2333;outline-offset:5px}\n.defiant-rebrand .dx-nav a{text-decoration:none;color:#34352e}\n.defiant-rebrand .dx-hero{display:grid;grid-template-columns:1.65fr 1fr;gap:70px;align-items:center;padding:76px 0 72px}\n.defiant-rebrand .dx-eyebrow{font-size:11px;font-weight:650;letter-spacing:.16em;line-height:1.5;text-transform:uppercase;color:#9d2333;margin:0 0 20px}\n.defiant-rebrand h1,.defiant-rebrand h2,.defiant-rebrand h3{font-family:Cardo,Georgia,serif;font-weight:400;letter-spacing:-.035em;color:#292a23;text-wrap:balance}\n.defiant-rebrand h1{font-size:clamp(45px,4.9vw,68px);line-height:1.04;margin:0 0 26px}\n.defiant-rebrand h2{font-size:clamp(34px,3.4vw,46px);line-height:1.1;margin:0 0 24px}\n.defiant-rebrand h3{font-size:27px;line-height:1.2;margin:0 0 14px}\n.defiant-rebrand p{margin-top:0;margin-bottom:18px}\n.defiant-rebrand .dx-intro{font-size:18px;line-height:1.65;max-width:640px;color:#55574f}\n.defiant-rebrand .wp-block-buttons{display:flex;gap:14px;flex-wrap:wrap;margin:28px 0 0}\n.defiant-rebrand .wp-block-button__link{border-radius:2px;padding:13px 21px;font-family:Inter,Arial,sans-serif;font-size:13px;font-weight:600;color:#fff;background:#9d2333;line-height:1.4;text-decoration:none;border:1px solid #9d2333}\n.defiant-rebrand .wp-block-button__link:hover{background:#7e1c2a;color:#fff}\n.defiant-rebrand .dx-secondary .wp-block-button__link{background:transparent;color:#9d2333}\n.defiant-rebrand .dx-origin{font-size:12px;color:#74766b;margin:24px 0 0}\n.defiant-rebrand .dx-diagram{border:1px solid #d7d3c7;padding:30px;background:#efede4;border-radius:4px}\n.defiant-rebrand .dx-diagram h2{font-size:34px;margin-bottom:6px}\n.defiant-rebrand .dx-diagram-intro{font-size:13px;color:#66685e;margin-bottom:24px}\n.defiant-rebrand .dx-step{display:grid;grid-template-columns:28px 1fr;gap:16px;border-top:1px solid #d4cfc2;padding:16px 0;align-items:start}\n.defiant-rebrand .dx-number{font-size:11px;line-height:26px;color:#9d2333;border:1px solid #caa4a7;width:26px;height:26px;text-align:center;border-radius:50%;margin:0}\n.defiant-rebrand .dx-step p:last-child{font-size:14px;line-height:1.45;margin:3px 0}\n.defiant-rebrand .dx-caption{font-size:12px;line-height:1.5;color:#65665d;margin:10px 0 0}\n.defiant-rebrand .dx-section{padding:72px 0;border-top:1px solid #d9d6cc;scroll-margin-top:35px}\n.defiant-rebrand .dx-split{display:grid;grid-template-columns:1fr 1.3fr;gap:80px}\n.defiant-rebrand .dx-body{color:#55574f;max-width:660px}\n.defiant-rebrand .dx-cards{display:grid;grid-template-columns:repeat(3,1fr);gap:32px;margin-top:44px}\n.defiant-rebrand .dx-card{padding:26px 0 0;border-top:2px solid #9d2333}\n.defiant-rebrand .dx-card h3{font-size:25px}\n.defiant-rebrand .dx-card p{font-size:14px;color:#65665d;margin-bottom:0}\n.defiant-rebrand .dx-program{background:#8e2231;color:#fff;padding:54px;border-radius:4px;margin-top:0}\n.defiant-rebrand .dx-program h2,.defiant-rebrand .dx-program .dx-eyebrow{color:#fff}\n.defiant-rebrand .dx-program .dx-eyebrow{opacity:.72}\n.defiant-rebrand .dx-program .dx-body{color:#f0dfe0}\n.defiant-rebrand .dx-stage{display:inline-block;border:1px solid #c67e87;border-radius:30px;padding:5px 12px;font-size:11px;letter-spacing:.06em}\n.defiant-rebrand .dx-paper{padding:21px 0;border-top:1px solid #d9d6cc}\n.defiant-rebrand .dx-paper p{margin:4px 0;font-size:14px;color:#65665d}\n.defiant-rebrand .dx-paper a{font-size:16px}\n.defiant-rebrand .dx-note{font-size:12px;color:#797a70;margin-top:20px}\n.defiant-rebrand .dx-team{display:grid;grid-template-columns:1fr 1fr;gap:50px;margin-top:34px}\n.defiant-rebrand .dx-person{display:grid;grid-template-columns:140px 1fr;gap:25px}\n.defiant-rebrand .dx-portrait{margin:0}\n.defiant-rebrand .dx-portrait img{width:140px;height:168px;object-fit:cover;object-position:center;border-radius:3px}\n.defiant-rebrand .dx-person h3{font-size:26px;margin:0 0 6px}\n.defiant-rebrand .dx-person p{font-size:13px;color:#65665d;margin:0 0 12px}\n.defiant-rebrand .dx-person .dx-role{font-size:11px;font-weight:600;color:#9d2333;text-transform:uppercase;letter-spacing:.04em}\n.defiant-rebrand .dx-contact{display:flex;align-items:center;justify-content:space-between;gap:35px;padding:58px 0}\n.defiant-rebrand .dx-contact h2{margin-bottom:12px}\n.defiant-rebrand .dx-contact p{margin:0;font-size:15px;color:#65665d}\n.defiant-rebrand .dx-email{font-family:Cardo,Georgia,serif;font-size:30px;white-space:nowrap}\n.defiant-rebrand .dx-footer{border-top:1px solid #d9d6cc;padding:24px 0 35px;display:flex;justify-content:space-between;gap:20px}\n.defiant-rebrand .dx-footer p{font-size:10px;color:#797a70;margin:0}\n@media(max-width:900px){.defiant-rebrand .dx-wrap{width:calc(100% - 48px)}.defiant-rebrand .dx-hero{gap:34px;grid-template-columns:1.4fr 1fr}.defiant-rebrand h1{font-size:48px}.defiant-rebrand .dx-split{gap:40px}.defiant-rebrand .dx-team{gap:32px}.defiant-rebrand .dx-person{grid-template-columns:1fr}.defiant-rebrand .dx-portrait img{width:140px;height:160px}.defiant-rebrand .dx-program{padding:36px}.defiant-rebrand .dx-email{font-size:25px}}\n@media(max-width:640px){.defiant-rebrand .dx-wrap{width:calc(100% - 40px)}.defiant-rebrand .dx-header{padding:22px 0;align-items:flex-start;gap:20px;flex-direction:column}.defiant-rebrand .dx-logo{width:150px}.defiant-rebrand .dx-nav{gap:22px;font-size:12px}.defiant-rebrand .dx-hero{display:block;padding:45px 0}.defiant-rebrand h1{font-size:45px;max-width:440px}.defiant-rebrand .dx-intro{font-size:16px}.defiant-rebrand .dx-diagram{margin-top:38px;padding:26px}.defiant-rebrand .dx-section{padding:45px 0}.defiant-rebrand .dx-split,.defiant-rebrand .dx-cards,.defiant-rebrand .dx-team{grid-template-columns:1fr;gap:26px}.defiant-rebrand .dx-cards{margin-top:30px}.defiant-rebrand .dx-program{padding:30px 24px}.defiant-rebrand .dx-program .dx-split{gap:8px}.defiant-rebrand .dx-person{grid-template-columns:105px 1fr;gap:20px}.defiant-rebrand .dx-portrait img{width:105px;height:130px}.defiant-rebrand .dx-person h3{font-size:24px}.defiant-rebrand .dx-contact{display:block;padding:44px 0}.defiant-rebrand .dx-contact .dx-email{margin-top:22px;font-size:28px;white-space:normal}.defiant-rebrand .dx-footer{display:block}.defiant-rebrand .dx-footer p+p{margin-top:8px}}\n\n.defiant-rebrand .dx-hero>*,.defiant-rebrand .dx-split>*,.defiant-rebrand .dx-cards>*,.defiant-rebrand .dx-team>*,.defiant-rebrand .dx-person>*{margin-block-start:0}\n.defiant-rebrand .dx-contact p.dx-email{font-size:30px;color:#9d2333}\n.defiant-rebrand .dx-person p{font-size:14px}\n.defiant-rebrand .dx-person p.dx-role{font-size:11px}\n@media(max-width:640px){.defiant-rebrand .dx-contact p.dx-email{font-size:28px;margin-top:22px}}\n.defiant-rebrand .dx-origin-banner{display:grid;grid-template-columns:170px 1fr;gap:36px;align-items:start;padding:28px 0;border-top:1px solid #d9d6cc}\n.defiant-rebrand .dx-origin-banner .dx-eyebrow{margin:0}\n.defiant-rebrand .dx-origin-banner p:last-child{margin:0;font-size:15px;color:#55574f}\n.defiant-rebrand .dx-ip{padding:40px 0}\n.defiant-rebrand .dx-ip h3,.defiant-rebrand .dx-ip p{margin-bottom:0}\n.defiant-rebrand .dx-program h3{color:#fff;font-size:25px;margin-top:26px}\n@media(max-width:640px){.defiant-rebrand .dx-origin-banner{grid-template-columns:1fr;gap:12px;padding:24px 0}.defiant-rebrand .dx-ip{padding:32px 0}}\n@media(max-width:640px){.defiant-rebrand .dx-hero>.dx-diagram{margin-top:38px}}\n\n\/* Compact lead program panel and adjacent spacing. *\/\n.defiant-rebrand #science{padding-bottom:32px}\n.defiant-rebrand #program.dx-section{padding:24px 0 28px;margin-block-start:0;border-top:0}\n.defiant-rebrand #program+.dx-section{padding-top:32px;margin-block-start:0}\n.defiant-rebrand #program .dx-program{padding:28px 38px}\n.defiant-rebrand #program .dx-split{grid-template-columns:minmax(0,1fr) minmax(0,1.65fr);gap:48px;align-items:center}\n.defiant-rebrand #program .dx-eyebrow{margin-bottom:12px}\n.defiant-rebrand #program h2{font-size:36px;margin-bottom:16px}\n.defiant-rebrand #program .dx-stage{margin-bottom:0}\n.defiant-rebrand #program .dx-body{font-size:16px;line-height:1.55}\n.defiant-rebrand #program .dx-body p{margin-bottom:12px}\n.defiant-rebrand #program .dx-body p:last-child{margin-bottom:0}\n.defiant-rebrand #program h3{font-size:24px;margin:12px 0 10px}\n@media(max-width:900px){.defiant-rebrand #program .dx-program{padding:28px}.defiant-rebrand #program .dx-split{gap:30px}.defiant-rebrand #program h2{font-size:34px}}\n@media(max-width:640px){.defiant-rebrand #science{padding-bottom:24px}.defiant-rebrand #program.dx-section{padding:12px 0 20px}.defiant-rebrand #program+.dx-section{padding-top:28px}.defiant-rebrand #program .dx-program{padding:26px 24px}.defiant-rebrand #program .dx-split{grid-template-columns:1fr;gap:18px}.defiant-rebrand #program h2{font-size:32px}.defiant-rebrand #program h3{font-size:23px;margin-top:18px}}\n<\/style>\n\n\n\n<div class=\"wp-block-group defiant-rebrand is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group dx-wrap is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group dx-header is-layout-flow wp-block-group-is-layout-flow\">\n<figure class=\"wp-block-image size-full dx-logo\"><img loading=\"lazy\" decoding=\"async\" width=\"1234\" height=\"526\" src=\"https:\/\/defianttx.com\/wp-content\/uploads\/2026\/10\/defiant-logo.png\" alt=\"Defiant Therapeutics\" class=\"wp-image-52\" srcset=\"https:\/\/defianttx.com\/wp-content\/uploads\/2026\/10\/defiant-logo.png 1234w, https:\/\/defianttx.com\/wp-content\/uploads\/2026\/10\/defiant-logo-300x128.png 300w, https:\/\/defianttx.com\/wp-content\/uploads\/2026\/10\/defiant-logo-1024x436.png 1024w, https:\/\/defianttx.com\/wp-content\/uploads\/2026\/10\/defiant-logo-768x327.png 768w\" sizes=\"auto, (max-width: 1234px) 100vw, 1234px\" \/><\/figure>\n\n\n\n<p class=\"dx-nav wp-block-paragraph\"><a href=\"#science\">Science<\/a><a href=\"#program\">Lead program<\/a><a href=\"#team\">Team<\/a><a href=\"#contact\">Contact<\/a><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-group dx-hero is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group dx-hero-copy is-layout-flow wp-block-group-is-layout-flow\">\n<p class=\"dx-eyebrow wp-block-paragraph\">Immune organs for solid tumors<\/p>\n\n\n\n<h1 class=\"wp-block-heading\">Building immune organs to fight cancer from within.<\/h1>\n\n\n\n<p class=\"dx-intro wp-block-paragraph\">Defiant is developing ReCharge<sup>TM<\/sup>, an injectable platform designed to form immune organs inside tumors. Its antigen-agnostic approach enables use across solid tumors. Our first preclinical program targets platinum-resistant ovarian cancer.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"#science\">Explore the science<\/a><\/div>\n\n\n\n<div class=\"wp-block-button dx-secondary\"><a class=\"wp-block-button__link wp-element-button\" href=\"#contact\">Contact us<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-group dx-diagram is-layout-flow wp-block-group-is-layout-flow\">\n<h2 class=\"wp-block-heading\">ReCharge<sup>TM<\/sup><\/h2>\n\n\n\n<p class=\"dx-diagram-intro wp-block-paragraph\">Designed to organize both the attack on the tumor and lasting immune memory.<\/p>\n\n\n\n<div class=\"wp-block-group dx-step is-layout-flow wp-block-group-is-layout-flow\">\n<p class=\"dx-number wp-block-paragraph\">01<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A patient&#8217;s own immune cells<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-group dx-step is-layout-flow wp-block-group-is-layout-flow\">\n<p class=\"dx-number wp-block-paragraph\">02<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A supportive gel formulation<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-group dx-step is-layout-flow wp-block-group-is-layout-flow\">\n<p class=\"dx-number wp-block-paragraph\">03<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Injection into a tumor<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-group dx-step is-layout-flow wp-block-group-is-layout-flow\">\n<p class=\"dx-number wp-block-paragraph\">04<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">An immune organ forms inside the tumor<\/p>\n<\/div>\n\n\n\n<p class=\"dx-caption wp-block-paragraph\">Illustration of the intended ReCharge approach. In preclinical development.<\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-group dx-origin-banner is-layout-flow wp-block-group-is-layout-flow\">\n<p class=\"dx-eyebrow wp-block-paragraph\">origins<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The ReCharge platform is built on foundational research developed at the Wyss Institute at Harvard University, supported by ARPA-H funding.<\/p>\n<\/div>\n\n\n\n<div id=\"science\" class=\"wp-block-group dx-section is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group dx-split is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group is-layout-flow wp-block-group-is-layout-flow\">\n<p class=\"dx-eyebrow wp-block-paragraph\">The science<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Immunity works through organization.<\/h2>\n<\/div>\n\n\n\n<div class=\"wp-block-group dx-body is-layout-flow wp-block-group-is-layout-flow\">\n<p class=\"wp-block-paragraph\">Tertiary lymphoid structures (TLS) are immune organs that form inside some tumors. Like lymph nodes, they give immune cells a place to learn and work together. In several studied cancer cohorts, TLS have been associated with longer survival and better response to immunotherapy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">ReCharge combines a supportive gel with the patient\u2019s own immune cells and is designed to form TLS at the tumor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Its antigen-agnostic design aims to engage many tumor antigens at once.<\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-group dx-cards is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group dx-card is-layout-flow wp-block-group-is-layout-flow\">\n<h3 class=\"wp-block-heading\">Organized immune architecture<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A supportive environment designed to help immune cells organize and work together.<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-group dx-card is-layout-flow wp-block-group-is-layout-flow\">\n<h3 class=\"wp-block-heading\">Local delivery<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">An injectable formulation designed for delivery at an accessible tumor site using standard clinical procedures.<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-group dx-card is-layout-flow wp-block-group-is-layout-flow\">\n<h3 class=\"wp-block-heading\">The patient\u2019s own cells<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">An autologous approach using a patient\u2019s immune cells, without genetic engineering.<\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div id=\"program\" class=\"wp-block-group dx-section is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group dx-program is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group dx-split is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group is-layout-flow wp-block-group-is-layout-flow\">\n<p class=\"dx-eyebrow wp-block-paragraph\">Platform &amp; lead program<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">A platform for solid tumors.<\/h2>\n\n\n\n<p class=\"dx-stage wp-block-paragraph\">PRECLINICAL DEVELOPMENT<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-group dx-body is-layout-flow wp-block-group-is-layout-flow\">\n<p class=\"wp-block-paragraph\">Our broader goal is to expand the same platform across solid-tumor types.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">We are starting with platinum-resistant ovarian cancer, where women urgently need new options.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Advancing toward clinical testing.<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Our next planned stage is a Phase 1 clinical trial, subject to regulatory clearance and further financing.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-group dx-section is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group dx-split is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group is-layout-flow wp-block-group-is-layout-flow\">\n<p class=\"dx-eyebrow wp-block-paragraph\">Research foundation<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Built on human immune biology.<\/h2>\n\n\n\n<p class=\"dx-body wp-block-paragraph\">Our approach builds on research at Harvard\u2019s Wyss Institute into how human immune cells organize into lymphoid structures.<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-group is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group dx-paper is-layout-flow wp-block-group-is-layout-flow\">\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/advanced.onlinelibrary.wiley.com\/doi\/10.1002\/advs.202103241\">Human lymphoid follicles in laboratory models \u2197<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Advanced Science \u00b7 2022<br>Human immune organization and influenza vaccine responses.<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-group dx-paper is-layout-flow wp-block-group-is-layout-flow\">\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.cell.com\/iscience\/fulltext\/S2589-0042(26)01791-8\">Modeling mRNA vaccine responses \u2197<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">iScience \u00b7 2026<br>An in vitro model for studying human vaccine responses.<\/p>\n<\/div>\n\n\n\n<p class=\"dx-note wp-block-paragraph\">These studies examine human immune organization and vaccine responses in laboratory models.<\/p>\n\n\n\n<p class=\"dx-note wp-block-paragraph\"><a href=\"https:\/\/wyss.harvard.edu\/news\/inodes-team-seeks-additional-support\/\">Read about the Wyss program \u2197<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-group dx-section dx-ip is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group dx-split is-layout-flow wp-block-group-is-layout-flow\">\n<h3 class=\"wp-block-heading\">Intellectual property<\/h3>\n\n\n\n<p class=\"dx-body wp-block-paragraph\">Defiant Therapeutics holds an option to negotiate an exclusive license with Harvard University for the core technology underlying the ReCharge platform.<\/p>\n<\/div>\n<\/div>\n\n\n\n<div id=\"team\" class=\"wp-block-group dx-section is-layout-flow wp-block-group-is-layout-flow\">\n<p class=\"dx-eyebrow wp-block-paragraph\">Our team<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Science and company-building experience.<\/h2>\n\n\n\n<div class=\"wp-block-group dx-team is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group dx-person is-layout-flow wp-block-group-is-layout-flow\">\n<figure class=\"wp-block-image size-full dx-portrait\"><img loading=\"lazy\" decoding=\"async\" width=\"900\" height=\"599\" src=\"https:\/\/defianttx.com\/wp-content\/uploads\/2026\/10\/sam-inverso.jpg\" alt=\"Sam Inverso, co-founder and CEO\" class=\"wp-image-53\" srcset=\"https:\/\/defianttx.com\/wp-content\/uploads\/2026\/10\/sam-inverso.jpg 900w, https:\/\/defianttx.com\/wp-content\/uploads\/2026\/10\/sam-inverso-300x200.jpg 300w, https:\/\/defianttx.com\/wp-content\/uploads\/2026\/10\/sam-inverso-768x511.jpg 768w\" sizes=\"auto, (max-width: 900px) 100vw, 900px\" \/><\/figure>\n\n\n\n<div class=\"wp-block-group is-layout-flow wp-block-group-is-layout-flow\">\n<h3 class=\"wp-block-heading\">Sam Inverso, PhD<\/h3>\n\n\n\n<p class=\"dx-role wp-block-paragraph\">Co-founder &amp; CEO<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scientist, entrepreneur and company builder. Co-founded ReadCoor, acquired by 10x Genomics, and led business development and partnerships at Harvard\u2019s Wyss Institute.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.linkedin.com\/in\/samuel-inverso\/\">LinkedIn \u2197<\/a><\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-group dx-person is-layout-flow wp-block-group-is-layout-flow\">\n<figure class=\"wp-block-image size-full dx-portrait\"><img loading=\"lazy\" decoding=\"async\" width=\"674\" height=\"900\" src=\"https:\/\/defianttx.com\/wp-content\/uploads\/2026\/10\/girija-goyal.jpg\" alt=\"Girija Goyal, co-founder and CSO\" class=\"wp-image-54\" srcset=\"https:\/\/defianttx.com\/wp-content\/uploads\/2026\/10\/girija-goyal.jpg 674w, https:\/\/defianttx.com\/wp-content\/uploads\/2026\/10\/girija-goyal-225x300.jpg 225w\" sizes=\"auto, (max-width: 674px) 100vw, 674px\" \/><\/figure>\n\n\n\n<div class=\"wp-block-group is-layout-flow wp-block-group-is-layout-flow\">\n<h3 class=\"wp-block-heading\">Girija Goyal, PhD<\/h3>\n\n\n\n<p class=\"dx-role wp-block-paragraph\">Co-founder &amp; CSO<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Immunologist, bioengineer, and inventor of ReCharge. Her research focuses on human immune tissue and lymphoid biology. She developed the foundational technology at Harvard\u2019s Wyss Institute, supported by ARPA-H funding, before co-founding Defiant to drive commercialization.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.linkedin.com\/in\/girija-goyal-01b5781b\/\">LinkedIn \u2197<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div id=\"contact\" class=\"wp-block-group dx-section dx-contact is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group is-layout-flow wp-block-group-is-layout-flow\">\n<h2 class=\"wp-block-heading\">Connect with Defiant.<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">For research, development and general inquiries.<\/p>\n<\/div>\n\n\n\n<p class=\"dx-email wp-block-paragraph\"><a href=\"mailto:info@defianttx.com\">info@defianttx.com \u2197<\/a><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-group dx-footer is-layout-flow wp-block-group-is-layout-flow\">\n<p class=\"wp-block-paragraph\">\u00a9 2026 Defiant Therapeutics. All rights reserved.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.linkedin.com\/company\/defianttx\/\">Defiant on LinkedIn <\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">ReCharge is in preclinical development.<\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ScienceLead programTeamContact Immune organs for solid tumors Building immune organs to fight cancer from within. Defiant is developing ReChargeTM, an injectable platform designed to form immune organs inside tumors. Its antigen-agnostic approach enables use across solid tumors. Our first preclinical program targets platinum-resistant ovarian cancer. ReChargeTM Designed to organize both the attack on the tumor [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-no-title","meta":{"footnotes":""},"class_list":["post-55","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/defianttx.com\/index.php?rest_route=\/wp\/v2\/pages\/55","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/defianttx.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/defianttx.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/defianttx.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/defianttx.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55"}],"version-history":[{"count":5,"href":"https:\/\/defianttx.com\/index.php?rest_route=\/wp\/v2\/pages\/55\/revisions"}],"predecessor-version":[{"id":89,"href":"https:\/\/defianttx.com\/index.php?rest_route=\/wp\/v2\/pages\/55\/revisions\/89"}],"wp:attachment":[{"href":"https:\/\/defianttx.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}